Neurocrine Biosciences Inc

Research Neurocrine Biosciences Inc (NBIX) on Bullrun: valuation model: 5.8% undervalued, market cap USD 17.09B, P/E 26.1. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNBIX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryDrug Manufacturers-Specialty & Generic
• CurrencyUSD
• Valuation signal5.8% undervalued
• Market capUSD 17.09B
• P/E26.1
• Financial periodFY2025
• RevenueUSD 2.86B
• Revenue growth21.4%
• Net incomeUSD 478.60M
• Free cash flowUSD 748.70M
• Gross margin98.2%

Valuation Snapshot

Bullrun's latest valuation model marks Neurocrine Biosciences Inc as 5.8% undervalued; latest market cap is USD 17.09B; P/E is 26.1.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.

Frequently asked questions

Is Neurocrine Biosciences Inc overvalued or undervalued?

Bullrun's valuation model currently marks Neurocrine Biosciences Inc as 5.8% undervalued.

What is Neurocrine Biosciences Inc's market cap?

Neurocrine Biosciences Inc's market capitalization is USD 17.09B.

What is Neurocrine Biosciences Inc's P/E ratio?

Neurocrine Biosciences Inc's price-to-earnings (P/E) ratio is 26.1.

What does Neurocrine Biosciences Inc do?

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.